TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05284773

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Caretaker MUAC screening - training by health workers
Description: Study personnel will train caregivers to conduct weekly AM screening using the color-coded MUAC tape. AM screening will involve identifying the midpoint of the child's right arm, wrapping the tape around the mid-point, inserting one end of the tape through the slit at the other end, pulling the tape secure, and reading the measurement based on the color bands. Caregivers will be trained to refer children with yellow or red readings to the nearest CSPS and will be provided with a referral slip to do so. Caregivers will be informed of the signs, symptoms, and consequences of malnutrition as well as the available nutritional programs. Study personnel will conduct monthly supervision visits including brief refresher trainings. In all study communities, standard of care screening for AM will continue. This includes biannual community-based screening by community health workers as well as weekly malnutrition days led by the CSPS.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Caretaker MUAC screening - training by caregivers
Description: Study personnel will train a group of caregivers to perform AM training of all caregivers living in their communities. they will instruct caregivers to conduct weekly AM screening. Training will include the same information as the communities receiving training by Health workers: MUAC training and how to interpret MUAC as well as key concepts of malnutrition. Caregivers will be trained to refer children with yellow or red readings to the nearest CSPS and will be. In all study communities, standard of care screening for AM will continue. This includes biannual community-based screening by community health workers as well as weekly malnutrition days led by the CSPS.
Study: NCT05907759

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab SC
Description: Daratumumab SC (daratumumab and hyaluronidase) is administered subcutaneously (SC) as 1800 mg/30,000 units weekly for a total of 8 weeks (8 doses) followed by every 2 weeks for a total of 16 weeks (8 doses) followed by every 4 weeks for up to 96 weeks (24 doses)
Study: NCT06510933

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Heel cups in different BMI index and its correlation to physical activity in children
Description: Procedure: Group with muscle retraction will use a 5 millimeter heel cups in 3 and 6 months
Study: NCT06422377

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Soticlestat
Description: Soticlestat tablets or mini-tablets
Study: NCT06472661

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Echopulse or Echopulse HD
Description: The Echopulse/Echopulse HD device delivers focused ultrasound ablation (FUSA) therapy. FUSA is a technology that delivers continuous high-intensity focused ultrasound to ablate (heat and destroy) tissue. A series of sound waves will be focused on the tumor using the Echopulse or the Echopulse HD device to cover the planned target area. The targeted area is 33% of the tumor, up to 3.5 cubic centimeters. An ultrasound will be used to guide the beam of the FUSA treatment to the targeted site. FUSA will be applied to up to two tumors in the session. Participants are sedated during the FUSA treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PolyICLC
Description: PolyICLC (polyinosinic-polycytidylic acid that is stabilized with carboxymethylcellulose and polylysine) is a drug that may help the body build an effective immune response to kill tumor cells. A single injection of .9 mg of polyICLC into one tumor will be given within 4 hours after the FUSA.
Study: NCT06333106

Intervention type: OTHER
Group type: OTHER
Intervention: POCUS diagnostic value
Description: Evaluation of the diagnostic value of clinical ultrasound in the diagnosis of fecal impaction in the emergency room
Study: NCT05763017

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Relative Motion Splint
Description: Six weeks relative motion splint wear.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Metacarpophalangeal Joint Blocking Splint
Description: Six weeks metacarpophalangeal joint blocking splint wear.
Study: NCT05846126

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RehabCovid_Telematic
Description: A multimodal and digitally-based cognitive training, physical exercise, and mindfulness intervention delivered remotely.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RehabCovid_ImmersiveVR
Description: A multimodal and digitally-based cognitive training, physical exercise and mindfulness intervention delivered face to face and through 360MK Virtual Reality technology

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control_Condition
Description: Traditional paper or pdf format multimodal intervention that will combine cognitive, mediation and physical activities.
Study: NCT04020029

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mindset
Description: Mindset Intervention will include watching three brief \~10-25 minute films

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reflection activities
Description: Reflection activity include exercises to internalize the message

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Reflection activities
Description: Reflection activity include exercises to internalize the message
Study: NCT05891600

Intervention type: DEVICE
Intervention: Smartclic
Description: The SmartClic® autoinjector is a reusable, electromechanical, and single-patient device for the administration of subcutaneously administered biologics.
Study: NCT05871541

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JCXH-105
Description: As IM injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Control (Shingrix)
Description: As IM injection
Study: NCT05905094

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Postural correction exercises
Description: Exercises to improve posture like shoulder shrugging, chin tuckin, neck isometrics
Study: NCT04830423

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Medical ozone injection
Description: Patients in the ozone (O2-O3) injection group will be given intraarticular and periarticular knee injections 3 times as the first dose of 10 μg / ml, the second dose is 15 μg / ml, and the third dose is 20 μg / ml, each session in a volume of 10 ml. Patients will be evaluated according to the study criteria at the beginning, 4 and 12 weeks later by a blinded investigator.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: steroid injection group
Description: In the steroid injection group, 1 ml of betamethasone (6 mg / ml) will be injected once intraarticular knee injection. Patients will be evaluated according to the study criteria at the beginning, 4 and 12 weeks later by a blinded investigator.
Study: NCT05672654

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Blood draw
Description: Blood draw

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Blood draw
Description: Blood draw

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Blood draw
Description: Blood draw

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Blood draw
Description: Blood draw

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Blood draw
Description: Blood draw

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Blood draw
Description: Blood draw
Study: NCT06552286

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: STRW-T
Description: The STRW-T intervention consists of 15 weekly caregiver group sessions and caregiver-teen dyad sessions delivered via Zoom. The targeted daily living skills (DLS) have been identified and refined through our prior studies and include: Morning routine, laundry, kitchen/cooking, grocery shopping, and money management. Evidence-based strategies are utilized to facilitate acquisition, mastery, and generalization of specific DLS at home and in the community. During dyad sessions, teens will work on DLS in their home environment and will receive coaching and instruction from both their caregiver and the therapist. During caregiver group sessions, the therapist will discuss the content of dyad sessions and engage in problem solving with each caregiver (e.g., using and fading rewards, implementing strategies to increase success, teen motivation/buy-in).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PEERS-T
Description: PEERS-T is a 15-week intervention with concurrent caregiver and teen group telehealth sessions that target social skills (e.g., building friendships, conversing, dealing with bullying). PEERS-T was chosen as the control because it is one of the few evidence-based interventions for autistic adolescents and does not address daily living skills. PEERS-T is also matched to STRW-T on duration and is clinically meaningful to families.
Study: NCT06151418

Intervention type: DRUG
Intervention: Novel hormonal therapy
Description: As provided in real-world setting
Study: NCT05671692

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregnenolone
Description: Pregnenolone 250 mg BID x 14 DAYS, followed by Pregnenolone 500 mg BID x 14 DAYS, followed by Pregnenolone 1000 mg BID x thereafter for the remainder of the 8-week trial

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Same as active comparator, except placebo dispensed.
Study: NCT03679247

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention
Description: The intervention will be a clinical decision support (CDS) system that contains three main features: 1) methods to synthesize electronic health record (EHR) data in order to identify under-diagnosed chronic conditions (synthesize existing medical data to increase recognition of CKD and uncontrolled HTN in CKD patients and deliver management recommendations based on this evidence), 2) improve the design and content of the CDS using human factors methods, specifically usability testing, and 3) the use of two behavioral nudges (pre-checked default orders and an email to obtain commitment from PCPs to obtain their commitment to follow the CDS recommendations).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: Usual Care, PCP will receive an email with general information about CKD guidelines
Study: NCT05442840

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral and drugs already approved and available for diabetes management
Description: Pharmacists will review the patients information and medical history as well as drug coverage to discuss preferred treatment options to manage diabetes based on recommendations from Diabetes Canada treatment guidelines; all drugs have been approved and are available on the market; pharmacists will offer frequent follow up and provide basic diabetes education to the patient at each follow up appointment
Study: NCT05443191

Intervention type: DRUG
Intervention: Semaglutide
Description: Participants will be treated with commercially available oral semaglutide according to local label and to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available oral semaglutide has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the participant in this study.
Study: NCT06102954

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Falls prevention intervention including exercise and educational components
Description: This includes five domains of exercise (strength, balance, flexibility, coordination, and endurance) and educational components to manage other falls risk factors (polypharmacy, nutrition, pain, orthostatic hypotension, poor vision and environmental hazard evaluations).
Study: NCT05292794

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CereGate Software; BSN cDBS Programmer; BSN Burst Programmer
Description: CereGate's objective is to, with a single DBS system implanted in the standard STN location for PD:~(i) deliver conventional tonic DBS stimulation of STN-to mitigate dopamine-responsive symptoms; and concurrently (ii) deliver bursting DBS-induced cueing stimulation-to mitigate FOG.~The sole function of CereGate Software is to guide the clinician through a systematic investigation of the stimulation parameter space to thereby configure / tune CereGate Therapy for each participant. CereGate Software proposes parameters for the clinician to evaluate and assists in documenting the response. It does not send commands to, nor control the output of, the DBS System.
Study: NCT04982731

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Positive Assurance
Description: Positive assurance is a low-cost, non-pharmacological strategy commonly used by specialty clinics to manage anxiety in individuals with mTBI. Positive assurance is comprised of words of affirmation given to individuals with a medical condition by a healthcare provider that are centered on hope and positive recovery expectations (i.e., You will recover, This can be treated).
Study: NCT05851118

Intervention type: BEHAVIORAL
Intervention: Quantified analysis of walking during a crossing task between two walkers
Description: Functional test that reproduce a task of daily living.

Intervention type: BEHAVIORAL
Intervention: Quantified analysis of walking during a crossing task between two walkers
Description: Functional test that reproduce a task of daily living.
Study: NCT05971316

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Foam Roller
Description: General Warm-up + Foam Roller
Study: NCT04938908

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ophthalmic Probiotic
Description: Bacterial lysate of Lactobacillus sakei, hydroxypropylmethylcellulose (HPMC), boric acid, sodium chloride, purified water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ophthalmic Probiotic
Description: Bacterial lysate of Lactobacillus sakei, hydroxypropylmethylcellulose (HPMC), boric acid, sodium chloride, purified water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Opthalmic Placebo
Description: Placebo contains complete formulation of the active drug except for bacterial lysate of Lactobacillus sakei (i.e. HPMC, boric acid, sodium chloride, purified water)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Opthalmic Placebo
Description: Placebo contains complete formulation of the active drug except for bacterial lysate of Lactobacillus sakei (i.e. HPMC, boric acid, sodium chloride, purified water)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral Probiotic Capsule
Description: Live Lactobacillus sakei (5 billion cfus) in hydroxypropylmethylcellulose hard capsule, with maltodextrin excipient

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral Probiotic Capsule
Description: Live Lactobacillus sakei (5 billion cfus) in hydroxypropylmethylcellulose hard capsule, with maltodextrin excipient

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral Placebo Capsule
Description: Hydroxypropylmethylcellulose hard capsule, filled with maltodextrin excipient

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Oral Placebo Capsule
Description: Hydroxypropylmethylcellulose hard capsule, filled with maltodextrin excipient
Study: NCT06252181

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: electromagnetic pulsed therapy
Description: patients (20 elderly) with peripheral arterial disease who take their medications will receive one hour elliptical exercise ( exercise will be applied 3 times per the week for eight week) and 3 sessions per weeks of 8-week electromagnetic one-hour pulsed therapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: elliptical exercise
Description: patients (20 elderly) with peripheral arterial disease who take their medications will receive one hour elliptical exercise (n=20 patients, exercise will be applied 3 times per the week for eight week)
Study: NCT05308875

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PD1-BCMA-CART
Description: Single infusion of PD1-BCMA-CART administered intravenously (i.v.)
Study: NCT06410430

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ba-Duan-Jin
Description: Ba-Duan-Jin is a common form of self-healthcare Qigong exercise that has been practiced by Chinese people for at least eight hundred years.It consists of eight sets of simple movements. By combining meditation with slow, graceful ovements,deep breathing, and relaxation, Ba-Duan-Jin practitioners believe it has the ability to move vital energy (Qi) throughout the body. Ba-Duan-Jin is also considered to be a multicomponent intervention that integrates physical, psychosocial, emotional, spiritual, and behavioral elements. While the biological mechanisms remain unclear.
Study: NCT05192200

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-Beta Interferon (PF-06823859)
Description: IV infusion
Study: NCT04869631

Intervention type: OTHER
Intervention: The outcome of an intervention is not evaluated, but aortic stenosis and additional amyloidosis are compared.
Description: We aim to compare patients with aortic valve stenosis with and without cardiac amyloidosis.
Study: NCT05911542

Intervention type: BEHAVIORAL
Intervention: Survey
Description: Participants complete survey about pain management practices

Intervention type: BEHAVIORAL
Intervention: Survey
Description: Participants complete survey about pain management practices
Study: NCT05225311

Intervention type: OTHER
Intervention: Observation
Description: Patients will be followed by the registry for life-long outcomes.
Study: NCT05711576

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo mouthwash
Description: Patients were treated with non surgical peri-implant mucositis therapy with non-surgical sub-marginal peri-implant instrumentation plus the use of a placebo mouthwash

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Full mouth disinfection
Description: Patients were treated with non surgical peri-implant mucositis therapy with non-surgical sub-marginal peri-implant instrumentation plus the use of full mouth disinfection (FMD) approach
Study: NCT06092762

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK120
Description: subcutaneous injection every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK120
Description: subcutaneous injection every 2 weeks
Study: NCT05830500

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib Hydrochloride Capsule
Description: Anlotinib hydrochloride is a muti-target tyrosine kinase inhibitor that inhibits both tumor angiogenesis and tumor cell proliferation simultaneously.
Study: NCT03728907

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hearing aid fitting technique- audiologist or user-adjusted
Description: See information under 'arm' description

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hearing aid fitting technique- audiologist or user-adjusted
Description: See information under 'arm' description
Study: NCT05511181

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BioWave
Description: The BioWave device is called BioWaveGO. It is a FDA 510(k) cleared high frequency sinusoidal neurostimulator

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TENS
Description: The TENS device is called Intensity 5000. It is a FDA 510(k) cleared TENS device
Study: NCT06508411

Intervention type: OTHER
Intervention: Pain screening
Description: exploration of the relationship between pain and sexual health
Study: NCT04986163

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-invasive analgesia monitoring with ANSPEC-PRO monitor and MEDSTORM monitor
Description: The patients are monitored with two monitors under anesthesia: one monitor attached to the left hand and one monitor to the right hand. When one monitor is connected to the patient, the other monitor will be disconnected. The first monitor is ANSPEC and the second monitor used is MEDSTORM.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-invasive analgesia monitoring with ANSPEC-PRO monitor and MEDASENSE monitor
Description: The patients are monitored with two monitors under anesthesia: one monitor attached to the left hand and one monitor to the right hand. When one monitor is connected to the patient, the other monitor will be disconnected. The first monitor is ANSPEC-PRO and the second monitor used is MEDASENSE.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-invasive analgesia monitoring with MEDSTORM monitor and MEDASENSE monitor
Description: The patients are monitored with two monitors under anesthesia: one monitor attached to the left hand and one monitor to the right hand. When one monitor is connected to the patient, the other monitor will be disconnected. The first monitor is MEDSTORM and the second monitor used is MEDASENSE.
Study: NCT06172452

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Project Body Neutrality SSI
Description: Online, 30-minute self-guided intervention for youth ages 13-17

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Supportive Therapy SSI
Description: Online, 30-minute self-guided activity for youth ages 13-17
Study: NCT05920798

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Multi-epitope Folate Receptor Alpha-loaded Dendritic Cell Vaccine
Description: Given ID

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pheresis
Description: Undergo apheresis
Study: NCT05416333

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azelaic acid
Description: Subjects will use the topical formulation once daily on the scalp. The subjects will use the treatment for a total of 6 months

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: usual medication for CCCA
Description: Subjects will continue to use their already prescribed topical formulation once daily on the scalp. The subjects will use their treatment for a total of 6 months